Induction of prostaglandin D2 through the p38 MAPK pathway is responsible for the antipruritic activity of sertaconazole nitrate

Journal of Investigative Dermatology

Volumn 130, Issue 10, 2010, Pages 2448-2456

  Kaur, Simarna ^a   Sur, Runa ^a   Liebel, Frank T ^a   Southall, Michael D ^a  

^a JOHNSON AND JOHNSON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; LAROPIPRANT; MITOGEN ACTIVATED PROTEIN KINASE P38; PROSTAGLANDIN D2; SERTACONAZOLE; 4 METHOXY N METHYLPHENETHYLAMINE; ANTIFUNGAL AGENT; HISTAMINE; IMIDAZOLE DERIVATIVE; INDOLE DERIVATIVE; MK-0524; PROSTAGLANDIN RECEPTOR; PROSTANOID D RECEPTOR 1, MOUSE; THIOPHENE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL ACTIVATION; DRUG EFFECT; DRUG INHIBITION; DRUG MECHANISM; MAST CELL DEGRANULATION; MAST CELL LEUKEMIA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PRURITUS; RAT; ANIMAL; CELL LINE; CHEMICALLY INDUCED DISORDER; CYTOLOGY; DEGRANULATION; DRUG INTERACTION; INSTITUTE FOR CANCER RESEARCH MOUSE; MACROPHAGE; MAST CELL; METABOLISM; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; ANIMALS; ANTIFUNGAL AGENTS; CELL DEGRANULATION; CELL LINE; DRUG INTERACTIONS; HISTAMINE; IMIDAZOLES; INDOLES; MACROPHAGES; MAST CELLS; MICE; MICE, INBRED ICR; P-METHOXY-N-METHYLPHENETHYLAMINE; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROSTAGLANDIN D2; PRURITUS; RATS; RECEPTORS, PROSTAGLANDIN; THIOPHENES;

EID: 77956877505     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2010.152     Document Type: Article

References (46)

1. Agut J, Tarrida N, Sacristán A et al. (1996) Antiinflammatory activity of topically applied sertaconazole nitrate. Methods Find Exp Clin Pharmacol 18:233-234
2. Andoh T, Nagasawa T, Satoh M et al. (1998) Substance P induction of itch-associated response mediated by cutaneous NK1 tachykinin receptors in mice. J Pharmacol Exp Ther 286:1140-1145
3. Arai I, Takano N, Hashimoto Y et al. (2004) Prostanoid DP1 receptor agonist inhibits the pruritic activity in NC/Nga mice with atopic dermatitis. Eur J Pharmacol 505:229-235
4. Barsumian EL, Isersky C, Petrino MG et al. (1981) IgE-induced histaminerelease from rat basophilic leukemia cell lines: isolation of releasing and nonreleasing clones. Eur J Immunol 11:317-323
5. Borders AS, de Almeida L, Van Eldik LJ et al. (2008) The p38alpha mitogen-activated protein kinase as a central nervous system drug discovery target. BMC Neurosci 9(Suppl 2):S12
6. Cao H, Xiao L, Park G et al. (2008) An improved LC-MS/MS method for the quantification of prostaglandins E(2) and D(2) production in biological fluids. Anal Biochem 372:41-51
7. Chahdi A, Fraundorfer PF, Beaven MA (2000) Compound 48/80 activates mast cell phospholipase D via heterotrimeric GTP-binding proteins. J Pharmacol Exp Ther 292:122-130
8. Chan CL, Jones RL, Lau HY (2000) Characterization of prostanoid receptors mediating inhibition of histamine release from anti-IgE-activated rat peritoneal mast cells. Br J Pharmacol 129:589-597
9. Futaki N, Arai I, Sugimoto M et al. (2007) Role of prostaglandins on mechanical scratching-induced cutaneous barrier disruption in mice. Exp Dermatol 16:507-512
10. Hashimoto Y, Arai I, Tanaka M et al. (2005) Prostaglandin D2 inhibits IgE-mediated scratching by suppressing histamine release from mast cells. J Pharmacol Sci 98:90-93
11. Hirata M, Kakizuka A, Aizawa M et al. (1994) Molecular characterization of a mouse prostaglandin D receptor and functional expression of the cloned gene. Proc Natl Acad Sci USA 91:11192-11196
12. Honma Y, Arai I, Hashimoto Y et al. (2005) Prostaglandin D2 and prostaglandin E2 accelerate the recovery of cutaneous barrier disruption induced by mechanical scratching in mice. Eur J Pharmacol 518:56-62
13. Inagaki N, Nagao M, Igeta K et al. (2001) Scratching behavior in various strains of mice. Skin Pharmacol Appl Skin Physiol 14:87-96
14. Kämpfer H, Bräutigam L, Geisslinger G et al. (2003) Cyclooxygenase-1-coupled prostaglandin biosynthesis constitutes an essential prerequisite for skin repair. J Invest Dermatol 120:880-890
15. Kämpfer H, Schmidt R, Geisslinger G et al. (2005) Wound inflammation in diabetic ob/ob mice: functional coupling of prostaglandin biosynthesis to cyclooxygenase-1 activity in diabetes-impaired wound healing. Diabetes 54:1543-1551
16. Kanaoka Y, Urade Y (2003) Hematopoietic prostaglandin D synthase. Prostaglandins Leukot Essent Fatty Acids 69:163-167
17. Koibuchi Y, Ichikawa A, Nakagawa M et al. (1985) Histamine release induced from mast cells by active components of compound 48/80. Eur J Pharmacol 115:163-170 (Pubitemid 16222890)
18. Larsen GL, Henson PM (1983) Mediators of inflammation. Annu Rev Immunol 1:335-359
19. Lau HY, Chan CL (2001) Modulation of intracellular cyclic AMP in immunologically activated rat peritoneal mast cells by prostaglandin D2. Inflamm Res 50(Suppl 2):S61-2
20. Lewis RA, Soter NA, Diamond PT et al. (1982) Prostaglandin D2 generation after activation of rat and human mast cells with anti-IgE. J Immunol 129:1627-1631
21. Liebel F, Lyte P, Garay M et al. (2006) Anti-inflammatory and anti-itch activity of sertaconazole nitrate. Arch Dermatol Res 298:191-199
22. Park GY, Christman JW (2006) Involvement of cyclooxygenase-2 and prostaglandins in the molecular pathogenesis of inflammatory lung diseases. Am J Physiol Lung Cell Mol Physiol 290:L797-805
23. Peachell PT, MacGlashan DW Jr, Lichtenstein LM et al. (1988) Regulation of human basophil and lung mast cell function by cyclic adenosine monophosphate. J Immunol 140:571-579
24. Peters SP, MacGlashan DW Jr, Schulman ES et al. (1984) Arachidonic acid metabolism in purified human lung mast cells. J Immunol 132:1972-1979
25. Pfaller MA, Sutton DA (2006) Review of in vitro activity of sertaconazole nitrate in the treatment of superficial fungal infections. Diagn Microbiol Infect Dis 56:147-152
26. Ribotsky BM (2009) Sertaconazole nitrate cream 2% for the treatment of tinea pedis. Cutis 83:274-277
27. Rothman S (1941) Physiology of itching. Physiol Rev 21:357-381
28. Rothschild AM (1970) Mechanisms of histamine release by compound 48-80. Br J Pharmacol 38:253-262
29. Saklatvala J (2004) The p38 MAP kinase pathway as a therapeutic target in inflammatory disease. Curr Opin Pharmacol 4:372-377
30. Schwartz LB, Lewis RA, Seldin D et al. (1981) Acid hydrolases and tryptase from secretory granules of dispersed human lung mast cells. J Immunol 126:1290-1294
31. Senyshyn J, Baumgartner RA, Beaven MA (1998) Quercetin sensitizes RBL-2H3 cells to polybasic mast cell secretagogues through increased expression of Gi GTP-binding proteins linked to a phospholipase C signaling pathway. J Immunol 160:5136-5144
32. Ständer S, Streit M, Darsow U et al. (2006) [Diagnostic and therapeutic procedures in chronic pruritus]. J Dtsch Dermatol Ges 4:350-370
33. Ständer S, Weisshaar E, Luger TA (2008) Neurophysiological and neurochemical basis of modern pruritus treatment. Exp Dermatol 17:161-169
34. Sugimoto M, Arai I, Futaki N et al. (2006a) COX-1 inhibition enhances scratching behaviour in NC/Nga mice with atopic dermatitis. Exp Dermatol 15:582-588
35. Sugimoto M, Arai I, Futaki N et al. (2006b) Role of COX-1 and COX-2 on skin PGs biosynthesis by mechanical scratching in mice. Prostaglandins Leukot Essent Fatty Acids 75:1-8
36. Sur R, Babad JM, Garay M et al. (2008a) Anti-inflammatory activity of sertaconazole nitrate is mediated via activation of a p38-COX-2-PGE2 pathway. J Invest Dermatol 128:336-344
37. Sur R, Nigam A, Grote D et al. (2008b) Avenanthramides, polyphenols from oats, exhibit anti-inflammatory and anti-itch activity. Arch Dermatol Res 300:569-574
38. Swieter M, Midura RJ, Nishikata H et al. (1993) Mouse 3T3 fibroblasts induce rat basophilic leukemia (RBL-2H3) cells to acquire responsiveness to compound 48/80. J Immunol 150:617-624
39. Urade Y, Hayaishi O (2000) Prostaglandin D synthase: structure and function. Vitam Horm 58:89-120
40. Weinstein A, Berman B (2002) Topical treatment of common superficial tinea infections. Am Fam Physician 65:2095-2102
41. Weston MC, Peachell PT (1998) Regulation of human mast cell and basophil function by cAMP. Gen Pharmacol 31:715-719
42. Williams HC, Burney PG, Pembroke AC et al. (1994) The U.K. Working Party's Diagnostic Criteria for Atopic Dermatitis. III. Independent hospital validation. Br J Dermatol 131:406-416
43. Yamada P, Isoda H, Han JK et al. (2007) Inhibitory effect of fulvic acid extracted from Canadian sphagnum peat on chemical mediator release by RBL-2H3 and KU812 cells. Biosci Biotechnol Biochem 71:1294-1305
44. Yamashita H, Makino T, Mizukami H et al. (2007) Pharmacological characterization of a chronic pruritus model induced by multiple application of 2,4,6-trinitrochlorobenzene in NC mice. Eur J Pharmacol 563:233-239
45. Yosipovitch G, Papoiu AD (2008) What causes itch in atopic dermatitis? Curr Allergy Asthma Rep 8:306-311
46. Yosipovitch G (2004) Dry skin and impairment of barrier function associated with itch-new insights. Int J Cosmet Sci 26:1-7